XBiotech: Jumps after positive interim results for dermatitis treatment

XBiotech

13/09/2018 13:31

** Drug developer's shares  XBIT.O  jump ~26 pct to $3.75
premarket
    ** XBIT announces positive interim results from its open
label pilot study for atopic dermatitis treatment, Bermekimab
 urn:newsml:reuters.com:*:nGNE18Bnlk
    ** Co says study will now enrol 20 patients who would
receive higher weekly doses over an 8-week period
    ** Up to Wednesday's close, stock down ~26 pct this year

 (Reporting by Aakash Jagadeesh Babu in Bengaluru)
 ((Aakash.B@thomsonreuters.com; within the U.S. +16462238780,
outside the U.S. +91  80 67491576; Reuters Messaging:
Aakash.B.thomsonreuters.com@reuters.net))